)
)
)
NXT Biologics
Core technologies: A portfolio of anti-fungal therapeutics based on immunologic prevention and treatment.
Asset 1: NXT-2 is a first-in-class pan-fungal vaccine designed to protect against the most common causes of life-threatening and chronic fungal infections in individuals at high risk of infection. Asset 2: Pan-fungal monoclonal antibodies to prevent and treat fungal infections.
Patients at risk for chronic/life-threatening fungal infections: Recurrent Vulvovaginal Candidiasis [RVVC], Pulmonary Diseases (Severe Asthma; COPD; Cystic Fibrosis), Autoimmune/Inflammatory Diseases, Transplant Patients, Hematologic Cancers and other Cancers, Diabetes, infants and geriatric populations. Development stage: Pre-clinical/product development stage. Murine and NHP immunogenicity and efficacy data for major causes of invasive and chronic fungal infections: Pulmonary Aspergillosis, Invasive Candidiasis, Pneumocystis pneumonia and Candida vulvovaginitis.
Address
AtlantaGeorgia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)